ArticleRegenerative biomaterials2026
Recombinant humanized type III collagen improves ovarian function via ITGA2-mediated mitochondrial function restoration in granulosa cells and extracellular matrix remodeling.
Article in Regenerative biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ovarian puncture alters genes but not follicle growth in cyclophosphamide mice model.Reproduction & fertility · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian aging is characterized by depletion of the follicular reserve. The extracellular matrix (ECM) provides the essential microenvironmental niche for follicles, and aged-related alterations in ECM composition may adversely affect follicular dynamics. However, the precise relationship between matrix components and ovarian aging remains unclear. In this study, we first observed a marked reduction in type III collagen (Col III) as a key alteration associated with ovarian aging. Furthermore, we discovered that as a biomaterial, recombinant humanized type III collagen (rhCol III) ameliorated ovarian function in 12-month-old natural aging rats, evidenced by restored estrous cycles, increased ovarian index, elevated levels of anti-Müllerian hormone (AMH) and estradiol (E2) and enhanced folliculogenesis. Notably, rhCol III promoted the reorganization of the disorganized ovarian ECM into a highly ordered and dense structure, providing a supportive biological scaffold for follicular development. Additionally, supplementation of rhCol III could mitigate oxidative stress and mitochondrial dysfunction in aged granulosa cells (GCs), thereby preventing apoptosis and cellular senescence. Mechanistically, rhCol III bound to the integrin α2 (ITGA2) receptor on GCs and activated the PI3K/Akt signaling pathway. Our findings highlight Col III deficiency as a critical factor in ovarian aging and demonstrate that rhCol III supplementation rejuvenates the ovarian microenvironment via the ITGA2-PI3K/Akt axis, presenting a novel therapeutic strategy. Thus ITGA2 may represent a promising target for mitigating ovarian aging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.